CDR-Life to Present at the American Association for Cancer Research 2022 Annual Meeting

Zürich, Switzerland, March 22, 2022 – CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based T cell engager technology (M-gager®), today announced that preclinical data for the Company’s lead development candidate, CDR404, a first of its kind dual MAGE-A4 T-cell engager,  has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research Annual Meeting, being held April 8-13 in New Orleans, LA. 

Details for the poster presentation are as follows:

Abstract Number: 2891

Poster Title: Enhanced Anti-tumor Responses with a Novel Dual pMHC T-cell Engager Bispecific Antibody 

Session Number & Name: Therapeutic Antibodies 2

Session Date: Tuesday, April 12, 2022

Session Time: 9:00 AM – 12:30 PM

Presenter: Stephanie Jungmichel, Pharmacology Leader, CDR-Life

Categorised in:

This post was written by CDR Life Editor